Wendy Galpern - Publications

Affiliations: 
2002-2003 Neurology Harvard Medical School, Boston, MA, United States 

0/30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
Low-probability matches (unlikely to be authored by this person)
2020 Becker S, Granert O, Timmers M, Pilotto A, Van Nueten L, Roeben B, Salvadore G, Galpern WR, Streffer J, Scheffler K, Maetzler W, Berg D, Scarfone IL. Association of hippocampal subfields, CSF biomarkers and cognition in non-demented Parkinson's disease patients. Neurology. PMID 33219138 DOI: 10.1212/WNL.0000000000011224  0.01
2020 Van Kolen K, Malia TJ, Theunis C, Nanjunda R, Teplyakov A, Ernst R, Wu SJ, Luo J, Borgers M, Vandermeeren M, Bottelbergs A, Wintmolders C, Lacy E, Maurin H, Larsen P, ... ... Galpern W, et al. Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody. Journal of Alzheimer's Disease : Jad. PMID 32894244 DOI: 10.3233/Jad-200544  0.01
2020 Triana-Baltzer G, Van Kolen K, Theunis C, Moughadam S, Slemmon R, Mercken M, Galpern W, Sun H, Kolb H. Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid. Journal of Alzheimer's Disease : Jad. PMID 32831201 DOI: 10.3233/JAD-200463  0.01
2017 Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, et al. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology. PMID 29237794 DOI: 10.1212/Wnl.0000000000004798  0.01
2016 Hopfner F, Haubenberger D, Galpern WR, Gwinn K, Van't Veer A, White S, Bhatia K, Adler CH, Eidelberg D, Ondo W, Stebbins GT, Tanner CM, Helmich RC, Lenz FA, Sillitoe RV, et al. Knowledge gaps and research recommendations for essential tremor. Parkinsonism & Related Disorders. PMID 27769649 DOI: 10.1016/J.Parkreldis.2016.10.002  0.01
2016 Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, Adler CA, Barbano RL, Factor SA, Goetz CG, Jankovic J, Reich SG, Rodriguez RL, Severt WL, Zurowski M, et al. Clinimetric testing of the comprehensive cervical dystonia rating scale. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26971359 DOI: 10.1002/Mds.26534  0.01
2015 Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, McDonald WM, Marsh L, Rosen AR, Waliczek T, Wright LJ, Galpern WR, Stebbins GT. Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology. Movement Disorders Clinical Practice. 2: 135-141. PMID 27088112 DOI: 10.1002/Mdc3.12131  0.01
2015 Jinnah HA, Teller JK, Galpern WR. Recent developments in dystonia. Current Opinion in Neurology. 28: 400-5. PMID 26110799 DOI: 10.1097/WCO.0000000000000213  0.01
2015 Yan L, Hicks M, Winslow K, Comella C, Ludlow C, Jinnah HA, Rosen AR, Wright L, Galpern WR, Perlmutter JS. Secured web-based video repository for multicenter studies. Parkinsonism & Related Disorders. 21: 366-71. PMID 25630890 DOI: 10.1016/J.Parkreldis.2015.01.011  0.01
2015 Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK. Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 285. PMID 25608934 DOI: 10.1007/s13311-014-0323-9  0.01
2015 Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE. Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 150-9. PMID 25607799 DOI: 10.1002/Mds.26099  0.01
2015 Galpern WR. Clinical trials for multiple system atrophy. The Lancet. Neurology. 14: 126-7. PMID 25498733 DOI: 10.1016/S1474-4422(14)70311-4  0.01
2015 Cedarbaum JM, Stephenson D, Rudick R, Carrillo MC, Stebbins G, Kerr D, Heemskerk J, Galpern WR, Kaufmann P, Cella D, Isaac M, Walton MK. Commonalities and challenges in the development of clinical trial measures in neurology. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 151-69. PMID 25384682 DOI: 10.1007/s13311-014-0310-1  0.01
2014 Sieber BA, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR, Dunlop J, Finkbeiner S, Sutherland M, Wang H, Lee VM, Orr HT, Gwinn K, Ludwig K, Taylor A, et al. Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. Annals of Neurology. 76: 469-72. PMID 25164235 DOI: 10.1002/Ana.24261  0.01
2014 Montine TJ, Koroshetz WJ, Babcock D, Dickson DW, Galpern WR, Glymour MM, Greenberg SM, Hutton ML, Knopman DS, Kuzmichev AN, Manly JJ, Marder KS, Miller BL, Phelps CH, Seeley WW, et al. Recommendations of the Alzheimer's disease-related dementias conference. Neurology. 83: 851-60. PMID 25080517 DOI: 10.1212/Wnl.0000000000000733  0.01
2014 Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. Jama Neurology. 71: 543-52. PMID 24664227 DOI: 10.1001/Jamaneurol.2014.131  0.01
2014 Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser RA, Cheshire W, Lessig S, Vernino S, Mandrekar J, Dupont WD, Chelimsky T, ... Galpern WR, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 13: 268-75. PMID 24507091 DOI: 10.1016/S1474-4422(13)70301-6  0.01
2014 Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JL, Yeatts SD, et al. Designing clinical trials for dystonia. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 117-27. PMID 24282121 DOI: 10.1007/S13311-013-0221-6  0.01
2013 Jinnah HA, Berardelli A, Comella C, Defazio G, Delong MR, Factor S, Galpern WR, Hallett M, Ludlow CL, Perlmutter JS, Rosen AR. The focal dystonias: current views and challenges for future research. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 926-43. PMID 23893450 DOI: 10.1002/Mds.25567  0.01
2012 Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1392-7. PMID 22976926 DOI: 10.1002/Mds.25157  0.01
2012 Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, Piantadosi S, Comstock Rick A, Federoff HJ. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. The Lancet. Neurology. 11: 643-50. PMID 22710757 DOI: 10.1016/S1474-4422(12)70064-9  0.01
2010 Schneider JS, Elm JJ, Parashos SA, Ravina BM, Galpern WR. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Parkinsonism & Related Disorders. 16: 507-12. PMID 20598621 DOI: 10.1016/J.Parkreldis.2010.06.001  0.01
2009 Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, et al. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 2081-90. PMID 19691116 DOI: 10.1002/Mds.22690  0.01
2007 Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 2268-73. PMID 17876852 DOI: 10.1002/mds.21730  0.01
2007 Galpern WR, Cudkowicz ME. Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion. 7: S146-53. PMID 17485247 DOI: 10.1016/j.mito.2007.01.004  0.01
2007 Galpern WR, Stacy M. Management of impulse control disorders in Parkinson's disease. Current Treatment Options in Neurology. 9: 189-97. PMID 17445496 DOI: 10.1007/Bf02938408  0.01
2007 Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1061-8. PMID 17266092 DOI: 10.1002/Mds.21382  0.01
2007 Tilley BC, Galpern WR. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke; a Journal of Cerebral Circulation. 38: 800-3. PMID 17261742 DOI: 10.1161/01.STR.0000255227.96365.37  0.01
2006 Galpern WR, Singhal AB. Neuroprotection: lessons from a spectrum of neurological disorders. International Journal of Stroke : Official Journal of the International Stroke Society. 1: 97-9. PMID 18706052 DOI: 10.1111/j.1747-4949.2006.00023.x  0.01
2006 Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Annals of Neurology. 59: 449-58. PMID 16489609 DOI: 10.1002/ana.20819  0.01
Hide low-probability matches.